- MSKCC’s Howard Scher presented findings for the investigational oral drug MDV3100 at the 2012 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
- Dr. Monica Morrow of MSKCC was quoted in a New York Times article about a study that examined the outcomes of breast cancer surgeries in women from four institutions and three health plans.
- MSKCC researchers reported that a scale used to measure bone metastases has been found useful in determining whether some prostate cancer patients are responding to chemotherapy. The study was published in the Journal of Clinical Oncology.
Resource Highlights: National Science Foundation
The National Science Foundation (NSF) is your portal for recent scientific discoveries, new research, scientific awards, statistics, funding opportunities and much more. Continue reading
Alert: Nuclear Medicine FOA
For those who work in the field of nuclear medicine, the US Department of Energy’s Office of Biological and Environmental Research recently issued a FOA for Integrated Nuclear Medicine Research and Training Projects of Excellence. It expects that up to $10M will be available in FY2012 for multiple awards. The pre-application due date is February 23.
The FOA specifies that “Institutional settings with easy access to nuclear medicine imaging specialties such as positron emission tomography (PET) and SPECT (single photon emission computed tomography) are required and should offer broad ranging research collaborations from research and development of radiotracers to translation for potential clinical use in humans.”